Drug
Bemarituzumab clinical trials
Also written FPA144 and AMG 552.
- studies test it
- 13
- open now
- 1
- in phase 3
- 2
- first study started
- 2014
Keep track of what changes. Save the bemarituzumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
13 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2022 | 4 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 7
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 5
Amgen (5) · Five Prime Therapeutics, Inc. (3) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · University of Chicago (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Centre Leon Berard (1) · Institut Cancerologie de l'Ouest (1)
Often tested with
Tested in the same studies.
Ramucirumab (2) · Paclitaxel (1) · Irinotecan (1) · Trifluridine (1) · Tipiracil (1) · Modified FOLFOX6 Regimen (1) · Trastuzumab (1) · Depatuxizumab (1)
Studies
Open first, then newest update. How each study uses bemarituzumab is read from its arms, and is right about nine times in ten.
Testing it · 13
- Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative TreatmentNot yet recruitingPhase 1European Organisation for Research and Treatment of Cancer - EORTCNCT06978062Written as Bemarituzumab
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedPhase 3AmgenNCT05052801Written as Bemarituzumab
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedPhase 3AmgenNCT05111626Written as Bemarituzumab
- A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.TerminatedPhase 1/2AmgenNCT05322577Written as Bemarituzumab
- A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionTerminatedPhase 1/2AmgenNCT05325866Written as Bemarituzumab
- AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncerWithdrawnPhase 1/2Centre Leon BerardNCT07146919Written as Bemarituzumab
- Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2bWithdrawnPhase 2Institut Cancerologie de l'OuestNCT06967987Written as Bemarituzumab + Flot regimen
- Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative ChemotherapyActive, not recruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT06680622Written as bemarituzumab, paclitaxel, ramucirumab
- Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid TumorsCompletedPhase 1Five Prime Therapeutics, Inc.NCT02318329Written as FPA144
- A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal CancerCompletedPhase 1Five Prime Therapeutics, Inc.NCT03343301Written as Bemarituzumab
- A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedPhase 2Five Prime Therapeutics, Inc.NCT03694522Written as Bemarituzumab
- A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal CancerCompletedPhase 1AmgenNCT05913115Written as FPA144
- PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond ProgressionCompletedPhase 2University of ChicagoNCT02213289Written as Bemarituzumab
Given in every arm · 2 — bemarituzumab is usual care beside what is tested
- SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell CarcinomaNot yet recruitingPhase 2Fujian Cancer HospitalNCT07470840Written as Bemarituzumab
- A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)TerminatedPhase 1AmgenNCT05267470Written as Bemarituzumab
Codes
What other systems call bemarituzumab · ClinicalTrials.gg INT001576
- MeSH (NLM) C000714767bemarituzumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) RJW23BQ0KWBEMARITUZUMABConfirmed FDA, NLM
- NCI Thesaurus C120040BemarituzumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000714767 | bemarituzumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | RJW23BQ0KW | BEMARITUZUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C120040 | Bemarituzumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.